Targets & Mechanisms: RSVing for site zero 

 

Table 1. RSV pipeline. Only one product is marketed to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). At least 12 other compounds are being developed to prevent or treat RSV-induced respiratory disease.

Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Status

Vaccines

Novavax Inc. (NASDAQ:NVAX)

RSV F vaccine

Respiratory syncytial virus (RSV) vaccine targeting RSV viral fusion F protein formulated using Nanovax's recombinant nanoparticle technology

Phase II

AstraZeneca plc's (LSE:AZN; NYSE:AZN) MedImmune LLC unit

MEDI-559

Live attenuated RSV vaccine

Phase I

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

GSK3003891A

Immunostimulant vaccine

Phase I

Pan-adenovirus
type 3 (PanAd3)/modified vaccinia Ankara (MVA) virus RSV vaccine

Heterologous prime-boost regimen with vectors encoding a string of RSV F, N and M proteins bearing both B and T cell epitopes

Phase I

RSV vaccine

Vaccine based on the company's PanAd3/MVA virus RSV vaccine

Phase I

Antibodies

AstraZeneca/AbbVie Inc. (NYSE:ABBV)

Synagis palivizumab

Humanized mAb against RSV F

Marketed

MedImmune

Motavizumab (MEDI-524)

Humanized mAb against RSV F

Phase III

Ablynx N.V. (Euronext:ABLX)

ALX-0171

Single variable domain antibody fragment against RSV F

Phase I

Other modalities

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)/
Kyowa Hakko Kirin Co. Ltd.
(Tokyo:4151)

ALN-RSV01

Small interfering RNA targeting RSV nucleocapside gene

Phase II

Gilead Sciences Inc. (NASDAQ:GILD)

GS-5806

Undisclosed

Phase II

Arrow Therapeutics Ltd./Novartis AG (NYSE:NVS; SIX:NOVN)

RSV604

Nucleoprotein inhibitor

Phase II

MicroDose Therapeutx Inc.

MDT-637

Inhalable, small molecule, antiviral fusion inhibitor delivered using dry powder nebulizer technology

Phase I

Alios BioPharma Inc.

ALS-8176

Oral RSV nuceloside analog

Phase I